Track topics on Twitter Track topics that are important to you
Boehringer Ingelheim said it plans to shift the focus of its investigational compound BI 409306 to ongoing clinical trials with schizophrenia patients after the drug failed to outperform a placebo in Phase II trials with 450 patients for the indication Alzheimer's disease (AD).
Original Article: Boehringer Refocuses AD drug on SchizophreniaNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...